Prophylactic Activity of Biogenic Selenium Nanoparticles Against Chronic Toxoplasma gondii Infection.

Q3 Medicine
Amir Keyhani, Mojtaba Shakibaie, Hossein Mahmoudvand, Sareh Jahanbakhsh, Amir T Kareshk, Saeedeh Shojaee, Naser Ziaali
{"title":"Prophylactic Activity of Biogenic Selenium Nanoparticles Against Chronic <i>Toxoplasma gondii</i> Infection.","authors":"Amir Keyhani,&nbsp;Mojtaba Shakibaie,&nbsp;Hossein Mahmoudvand,&nbsp;Sareh Jahanbakhsh,&nbsp;Amir T Kareshk,&nbsp;Saeedeh Shojaee,&nbsp;Naser Ziaali","doi":"10.2174/1574891X15666200604115001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Studies showed that biogenic selenium nanoparticles (SeNPs) have a number of pharmacological properties, such as antimicrobial ones.</p><p><strong>Objective: </strong>The present investigation assesses the efficacy of biogenic selenium nanoparticles (SeNPs) as a new patent against latent toxoplasmosis in a mice model.</p><p><strong>Methods: </strong>Male BALB/c mice were orally treated with SeNPs at the doses of 2.5, 5, 10 mg/kg once a day for 14 days. On the 15th day, the mice were infected with the intraperitoneal inoculation of 20-25 tissue cysts from the Tehran strain of Toxoplasma gondii. The mean numbers of brain tissue cysts and the mRNA levels of TNF-α, IL-12, IL-10, IFN-γ, and inducible nitric oxide synthase (iNOS) in mice of each tested group were measured. Moreover, serum clinical chemistry factors in treated mice were examined to determine the safety of SeNPs.</p><p><strong>Results: </strong>The mean number of the brain tissue cysts was significantly (P<0.001) decreased in mice treated with SeNPs at doses 2.5 (n=37), 5 (n=11), and 10 mg/kg (n=3) based on a dose dependent manner compared with the control group (n=587). The mRNA levels of IFN-γ, TNF-α, IL-12, and iNO were significantly increased in mice treated with SeNPs at the doses 10 mg/kg compared with control subgroups (p<0.05). No significant variation (p>0.05) was observed in the clinical chemistry parameters among the mice in the control subgroups compared with groups treated with SeNPs.</p><p><strong>Conclusion: </strong>The results of the present study showed a new patent in the treatment of toxoplasmosis; so that taking the biogenic selenium nanoparticles in concentrations of 2.5-10 mg/kg for 2 weeks was able to prevent severe symptoms of the toxoplasmosis in a mice model. This indicated the prophylactic effects of SeNPs with no considerable toxicity against latent toxoplasmosis. However, more studies are required to elucidate the correct anti-Toxoplasma mechanisms of SeNPs.</p>","PeriodicalId":20909,"journal":{"name":"Recent patents on anti-infective drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on anti-infective drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574891X15666200604115001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 11

Abstract

Background: Studies showed that biogenic selenium nanoparticles (SeNPs) have a number of pharmacological properties, such as antimicrobial ones.

Objective: The present investigation assesses the efficacy of biogenic selenium nanoparticles (SeNPs) as a new patent against latent toxoplasmosis in a mice model.

Methods: Male BALB/c mice were orally treated with SeNPs at the doses of 2.5, 5, 10 mg/kg once a day for 14 days. On the 15th day, the mice were infected with the intraperitoneal inoculation of 20-25 tissue cysts from the Tehran strain of Toxoplasma gondii. The mean numbers of brain tissue cysts and the mRNA levels of TNF-α, IL-12, IL-10, IFN-γ, and inducible nitric oxide synthase (iNOS) in mice of each tested group were measured. Moreover, serum clinical chemistry factors in treated mice were examined to determine the safety of SeNPs.

Results: The mean number of the brain tissue cysts was significantly (P<0.001) decreased in mice treated with SeNPs at doses 2.5 (n=37), 5 (n=11), and 10 mg/kg (n=3) based on a dose dependent manner compared with the control group (n=587). The mRNA levels of IFN-γ, TNF-α, IL-12, and iNO were significantly increased in mice treated with SeNPs at the doses 10 mg/kg compared with control subgroups (p<0.05). No significant variation (p>0.05) was observed in the clinical chemistry parameters among the mice in the control subgroups compared with groups treated with SeNPs.

Conclusion: The results of the present study showed a new patent in the treatment of toxoplasmosis; so that taking the biogenic selenium nanoparticles in concentrations of 2.5-10 mg/kg for 2 weeks was able to prevent severe symptoms of the toxoplasmosis in a mice model. This indicated the prophylactic effects of SeNPs with no considerable toxicity against latent toxoplasmosis. However, more studies are required to elucidate the correct anti-Toxoplasma mechanisms of SeNPs.

生物源性纳米硒对慢性弓形虫感染的预防作用。
背景:研究表明,生物源性纳米硒(SeNPs)具有许多药理特性,如抗菌特性。目的:研究生物源性纳米硒(SeNPs)作为一种新专利对小鼠潜伏性弓形虫病的治疗效果。方法:雄性BALB/c小鼠口服SeNPs,剂量分别为2.5、5、10 mg/kg,每天1次,连用14 d。第15天,小鼠腹腔接种20 ~ 25个刚地弓形虫德黑兰株组织囊肿。测定各组小鼠脑组织囊肿的平均数量及TNF-α、IL-12、IL-10、IFN-γ和诱导型一氧化氮合酶(iNOS) mRNA水平。此外,还检测了治疗小鼠的血清临床化学因子,以确定SeNPs的安全性。结果:与SeNPs治疗组相比,对照组小鼠的临床化学参数中脑组织囊肿的平均数量有显著性差异(P0.05)。结论:本研究结果为弓形虫病的治疗开辟了新的专利;因此,在小鼠模型中,服用浓度为2.5 ~ 10 mg/kg的生物源性纳米硒2周可以预防严重的弓形虫病症状。这表明SeNPs对潜伏性弓形虫病的预防作用没有明显的毒性。然而,需要更多的研究来阐明SeNPs的正确抗弓形虫机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recent patents on anti-infective drug discovery
Recent patents on anti-infective drug discovery Medicine-Pharmacology (medical)
CiteScore
2.40
自引率
0.00%
发文量
1
期刊介绍: Recent Patents on Anti-Infective Drug Discovery publishes review articles on recent patents in the field of anti-infective drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-infective drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-infective drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信